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Apoptosis of THP-1 macrophage-derived foam cells induced by 5-aminolevulinic
acid-mediated sonodynamic therapy is mitochondria-caspase pathway
predominant despite the participation of endoplasmic reticulum stress
Wang Huan, Ye Tian
The ﬁrst afﬁliated hospital of Harbin Medical University
Objectives: In advanced atherosclerosis, chronic endoplasmic reticulum (ER) stress
induces foam cells apoptosis and generates inﬂammatory reactions. Sonodynamic
therapy (SDT) is a non-thermal synergistic method for cancer treatment utilizing
low-intensity ultrasound and sonosensitizers. 5-Aminolaevulinic acid (ALA) is the
biological precursor of sonosensitizer PpIX in the heme biosynthesis pathway in
mitochondria. In this study, we investigated the sub-cellular location of ALA-PpIX in
THP-1 macrophage-derived foam cells (FC) and the activation of mitochondria
pathway and ER stress induced by ALA-SDT.
Methods: FC were incubated with 1 mMALA. Fluorescence spectrometer was used to
detect the location and metabolism of ALA-PpIX in mitochondria and endoplasmic
reticulum (ER) of FC. Annexin V-PI staining was used to optimize ALA-SDT
treatment parameters by detecting the apoptotic and necrotic rates of FC induced by
ALA-SDT with different ALA incubation time and ultrasonic irradiation intensities.
Intracellular reactive oxygen species (ROS) level after ALA-SDT was detected
by staining with CellROX Green Reagent. Mitochondrial membrane potential
after ALA-SDT was detected by staining with JC-1. Pretreated with ROS inhibitor
N-acetylcysteine (NAC), pan-caspase inhibitor Z-VAD-FMK and ER stress inhibitor
4-phenylbutyrate (4-PBA), expressions of mitochondria apoptosis associated proteins
cytochromc c, cleaved caspase3, cleaved caspase9, Bcl-2, BAX and ER stress asso-
ciated protein C/EBP-homologous protein (CHOP) in FC after ALA-SDT were
detected by Western blotting.
Results: Accumulation of ALA-PpIX in mitochondria and ER reached peak at 6-hour,
and the ﬂuorescence intensity in mitochondria was triple of that in ER. The highest
percentage of apoptotic cells (63.6%9.8%) and the maximum apoptosis/necrosis
ratio (21.76.3) was observed at 5-hour after ALA-SDT with 6-hour incubation of
ALA and 0.4 W/cm2 ultrasound intensity. After ALA-SDT, intracellular ROS level
increased and the mitochondrial membrane potential collapsed. The translocations of
cytochrome c from mitochondria into cytosol and Bax from cytosol into mitochondria,
cleaved caspase 9, cleaved caspase 3, downregulation of Bcl-2, as well as upregulation
of CHOP were detected at 5-hour after ALA-SDT, which could be suppressed by
NAC. Activation of mitochondria apoptosis pathway could not be inhibited by 4-PBA.
Apoptosis induced by ALA-SDT could be inhibited by Z-VAD-FMK. 4-PBA reduced
FC apoposis by one third.
Conclusions: Mitochondria-caspase pathway is predominant in the apoptosis of FC
induced by ALA-SDT though ER stress participates in.
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Objectives: Endothelial progenitor cells (EPCs) -based therapy holds tremendous
promise for the treatment of ischemic diseases. However, the function and survival of
EPCs are dramatically impaired by oxidative stress. SIRT1 plays important roles in
many pathophysiological processes such as apoptosis by deacetylation various sub-
strates, including FOXO. However, little is known about the roles of SIRT1 in the
regulation of EPCs apoptosis induced by H2O2. Our previous work showed that
FOXO3a could promote apoptosis of EPCs by transcriptional regulation of Bim. In the
present study, we investigated whether SIRT1 exerted a protective effect against
H2O2-induced EPCs apoptosis and whether SIRT1 deacetylation of FOXO3a could
facilitate FOXO3a ubiquitination and subsequent degradation.
Methods: EPCs were isolated and obtained from human umbilical cord blood by
density gradient centrifugation. Incubation of EPCs with H2O2 was used to induce
apoptosis. Apoptosis was determined by ﬂow cytometry and DNA fragmentation.
Western Blot analysis was used to examine the expression of SIRT1, FOXO3a, Bax
and cleaved caspase 3. Adenoviral-mediated transfection was used to overexpress or
downregulate SIRT1. Co-immunoprecipitation (co-IP) assay was performed to test the
interaction between SIRT1 and FOXO3a, FOXO3a acetylation level and FOXO3a
ubiquitination level.
Results: Immunoﬂuorescence showed that SIRT1 localized in the nuclear of EPCs in
the absence or presence of H2O2. SIRT1 expression in EPCs was increased by the
treatment with H2O2 (500mM) for 24 hours. Incubation of EPCs with H2O2 dose
dependently induced EPCs apoptosis. SIRT1 overexpression reduced H2O2-induced
EPCs apoptosis, while SIRT1 downregulation and EX527, a speciﬁc SIRT1 inhibitor,
exerted the opposite effect. SIRT1 overexpression decreased the total FOXO3a
expression, whereas SIRT1 downregulation and EX527 increased the amount ofJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/BFOXO3a. Co-IP assay showed that SIRT1 could bind to FOXO3a, reduce its acety-
lation level and increase its ubiquitination level.
Conclusions: The results of our work demonstrated that SIRT1 had a pivotal pro-
tective role in the regulation of EPCs apoptosis induced by H2O2 and that SIRT1
protected against apoptosis by inhibiting FOXO3a via FOXO3a ubiquitination and
subsequent degradation.
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Pharmacogenetics of clopidogrel responsiveness in Chinese patients with acute
coronary syndrome
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Objectives: Cytochrome P450 (CYP), ATP-binding cassette transporters (ABCB1),
and paraoxonase-1 (PON1) play crucial roles in clopidogel metabolism. Genetic
polymorphisms in these genes have been associated with the variability of the
response to clopidogrel, however, there are controversies over the ﬁndings. The
objective of the study is to elucidate the contribution of genetic polymorphisms in
CYP2C19, ABCB1, and PON1, to clopidogrel responsiveness in Chinese acute cor-
onary syndrome (ACS) patients.
Methods: Five hundred Chinese-Han patients treated with clopidogrel for ACS were
consecutively recruited. We assessed the relationships of CYP2C19*2, CYP2C19*3,
CYP2C19*17, PON1Q129R and ABCB1C3435T to the on-treatment platelet reac-
tivity (OTPR) after 5 days maintenance dose of clopidogrel administration, and the
risk for high on-treatment platelet reactivity (HPR, deﬁned as 20mmol/L ADP-induced
platelet aggregation>50%). In addition, clopidogrel responsiveness, measured by RI
[(pretreatment aggregation-posttreatment aggregation at 5 days) / (pretreatment ag-
gregation) x100%], was assessed in relation to the genotypes in a subgroup of 180
patients. RI values were stratiﬁed into four quartiles, with patients in quartile 1 deﬁned
as individuals of clopidogrel non-responsiveness.
Results: Both CYP2C19*2 and *3 were signiﬁcantly associated with higher OTPR
(P<10-5 and P¼0.04, respectively). OTPR in carriers of at least one CYP2C19
loss-of-function allele (*2 or *3, accounted for 58% of the study population) was
obviously higher than that in CYP2C19 wild type carriers (P<10-5). The carriers of
at least one CYP2C19 loss-of-function allele could predict greater risk of HPR
(adjusted OR: 1.79, 95% CI: 1.33-2.4, P¼0.003). Patients with CYP2C19*2 alone,
instead of CYP2C19*3, had a higher risk for HPR (adjusted OR: 1.56; 95% CI
1.04-2.33, P¼0.03). No signiﬁcant relation of CYP2C19*17, PON1Q192R and
ABCB1C3435T to OTPR and HPR was found in the cohort. In the subgroup of
180 patients, RI values were signiﬁcantly lower in patients with PON1 192 QR
and RR than in patients with QQ alleles (P¼0.01). PON1 192 QR and RR
conferred increased risk for clopidogrel non-responsiveness [adjusted OR: 3.64;
95% CI (1.21-10.92), P¼0.02]. A trend for lower RI values was shown in
CYP2C19*2 carriers compared to CYP2C19 wild type carriers (P¼0.06). An
increased risk for clopidogrel non-responsiveness was found in patients with
CYP2C19*2 [adjusted OR 2.02; 95% CI (1.03-3.96), P¼0.04]. No signiﬁcant
relation of CYP2C19*3, CYP2C19*17, and ABCB1C3435T to RI was found in
the subgroup of patients.
Conclusions: In conclusion, in clopidogrel treated Chinese patients with ACS,
carriers of at least one CYP2C19 loss-of-function allele could predict greater
risk for HPR, with the impact mainly attributing to CYP2C19*2. Both PON1
Q192R and CYP2C19*2 genotypes inﬂuence clopidogrel responsiveness, with the
impact of PON1 Q192R mainly on relative platelet inhibition instead of HPR of
clopidogrel.
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Effect of intracoronary or intravenous tiroﬁban bolus administration on platelet
activity and short time clinic beneﬁt in patients with acute ST-segment elevation
myocardial infarction undergoing emergency interventional treatment
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Objectives: To investigate the effect on platelet activity and short time clinic beneﬁt
of intracoronary or intravenous tiroﬁban bolus administration to patients with acute
ST-segment elevation myocardial infarction undergoing emergency interventional
treatment.
Methods: Selected 90 patients with acute ST-segment elevation myocardial infarction
undergoing emergency interventional treatment, randomly divided into the intra-
coronary group (intracoronary tiroﬁban 10, 30 cases), intravenous group (intravenous
tiroﬁban 10 mg/kg bolus then 0.15 mg.kg-1.min-1 intravenous continuous infusion for
36 h, 30 cases) and control group (without tiroﬁban, 30 cases). The level of PMPs
were assessed before tiroﬁban infusion, at 10 min and 24 hours after tiroﬁban infusion,
and at 12 hours after stopping tiroﬁban infusion by the ﬂow cytometry. Clinical and
angiographic features were recorded and analyzed.
Results: There was no signiﬁcant difference in baseline of PMPs between intra-
coronary group, intravenous group and control group (P>0.05). The level of PMPs
were signiﬁcantly lower in intracoronary (3.6%2.3%) and intravenous groupasic and Translational Medicine C57
